Aptimmune

Based in St. Louis, Missouri, Aptimmune Biologics develops and manufactures nanoparticle-based mucosal vaccines for the global commercial swine industry to prevent major viral respiratory diseases in livestock. The biotechnology company utilizes its proprietary Barricade platform and ZMAC cell line technology to deliver intranasal autogenous vaccines targeting Porcine Reproductive and Respiratory Syndrome, Swine Influenza, and African Swine Fever. Serving veterinary clinics and commercial pork producers across multiple geographies, the enterprise has manufactured over 6 million vaccine doses to date, generating more than $2 million in revenue while securing over $9 million in disclosed venture funding. Aptimmune licenses its core technology from the University of Illinois and has received financial backing from institutional investors including Arsenal Capital Management and Kemin Industries, which subsequently acquired the entire business. The company was founded in 2010 by Dr. Federico Zuckermann.